RxDoctor Payments Data

Thomas Vradelis, MD

Obstetrics & Gynecology · Morehead City, NCNPI 1760424733

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Amgen at 47.4% of the total. That places this record below the midpoint for obstetrics & gynecology clinicians in NC, where the typical reported total is $453.

$264in general payments, 2019–2025

Across 3 payments — averaging $87.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$125
  • Angiodynamics, Inc.$104
  • Olympus America Inc.$34
$122,432in research payments, 2019–2025

Across 47 payments — averaging $2604.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bayer$83K
  • Cepheid$19K
  • Mitsubishi Tanabe Pharma Development America, Inc.$19K
  • Myovant Sciences Inc.$833

What the payments were for

  • Food & beverage$264100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen1$125
Angiodynamics, Inc.1$104
Olympus America Inc.1$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$264 in reported general payments places this provider in the 35th percentile of 1,344 obstetrics & gynecology providers in North Carolina.

See all obstetrics & gynecology providers in North Carolina

Medicare billing

Part B allowed, 2024
$176,136
Medicare patients
816
Services billed
2,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron17$8,115
Estradiol70$2,496
YuvafemEstradiol12$1,239
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet16$1,104
Raloxifene Hcl33$946
Oxybutynin Chloride ErOxybutynin Chloride53$503
Venlafaxine Hcl ErVenlafaxine Hcl18$477
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst15$187
Norethindrone Acetate13$181
Tramadol Hcl12$117
Medroxyprogesterone Acetate11$73
Fluconazole28$64

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Morehead City

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →